Description

Phenylpiracetam Carphedon Tablets

Phenylpiracetam Carphedon
CAS Number	77472-70-9
Molar Mass	218.256 g·mol−1
Chemical Formula	C12H14N2O2
IUPAC Name	(R,S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide

Introduction

Phenylpiracetam Carphedon Tablets is a novel research compound designed for scientific investigations, specifically in the fields of weight loss, cognitive enhancement, and physical energy. It is crucial to underscore that these tablets are strictly intended for research purposes, and any reference to human consumption is strictly prohibited.

Key Characteristics

Phenylpiracetam Carphedon is a nootropic compound, known for its potential cognitive benefits. It is derived from piracetam and exhibits unique pharmacological properties, making it a subject of interest in various scientific studies.

Research Applications

Researchers explore the diverse applications of Phenylpiracetam Carphedon Tablets in neuroscience, metabolism, and energy-related studies. The compound’s potential effects on weight loss, cognitive function, and physical energy make it a versatile tool in laboratory investigations.

Research Benefits

Phenylpiracetam Carphedon and Weight Loss

Studies suggest a potential link between Phenylpiracetam Carphedon and weight loss. Research investigates its influence on metabolic processes, appetite regulation, and related mechanisms to better understand its impact on body weight.

Phenylpiracetam Carphedon and The Brain

Phenylpiracetam Carphedon’s cognitive-enhancing properties are a focal point in neuroscience research. Investigations explore its effects on memory, learning, and overall cognitive function, shedding light on its potential applications in cognitive research.

Phenylpiracetam Carphedon and Physical Energy

The compound’s impact on physical energy is of interest in studies related to fatigue and physical performance. Researchers aim to elucidate the mechanisms through which Phenylpiracetam Carphedon may influence energy levels and endurance.

Summary

Phenylpiracetam Carphedon Tablets offer potential benefits in weight loss, cognitive enhancement, and physical energy research. As a research tool, these tablets contribute to our understanding of the compound’s effects on metabolism, cognition, and energy-related processes.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Zvejniece L, Svalbe B, Vavers E, Makrecka-Kuka M, Makarova E, Liepins V, Kalvinsh I, Liepinsh E, Dambrova M. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav. 2017 Sep;160:21-29. doi: 10.1016/j.pbb.2017.07.009. Epub 2017 Jul 22. PMID: 28743458. [Read More].
2. Tiurenkov IN, Bagmetov MN, Epishina VV. [Comparative evaluation of the neuroprotective activity of phenotropil and piracetam in laboratory animals with experimental cerebral ischemia]. Eksp Klin Farmakol. 2007 Mar-Apr;70(2):24-9. Russian. PMID: 17523446. [Read More].
3. Vasil’eva EV, Salimov RM, Kovalev GI. [Effects of nootropic drugs on behavior of BALB/c and C57BL/6 mice in the exploratory cross-maze test]. Eksperimental’naia i Klinicheskaia Farmakologiia. 2012 ;75(7):3-7. PMID: 23025044. [Read More].